Clean ScienceQ1 FY27
Clean Science Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹821P/E: 37.7Market Cap: ₹8.8K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →HALS business revenue is expected to grow to INR 250-300 crores annually, contributing around 30-35% of overall revenue growth in FY27, with export constituting nearly 50% of HALS sales.
- →HALS volume for the year is targeted above 3,000 metric tons, with consistent scale-up expected over next 2-3 years.
- →EBITDA margins for HALS are projected to improve due to higher-grade product mix and operational efficiencies.
- →Performance Chemical 2 plant commercialization expected by Q3 FY27, with revenues anticipated from Q1 FY28 after stabilization.
- →Strategic collaborations (Geneus Chem, Kemin) expected to enhance revenue streams, including an incremental INR 300 crores over 4 years from Geneus tie-up.
- →Export markets, especially the U.S. and Europe (via Netherlands subsidiary operational from mid-September), will support growth.
- →Supply chain stability and raw material availability are key targets for ensuring steady production and revenue ramp-up.
Margin guidance
Category 3- →EBITDA margins are expected to improve over the next 2-3 years due to increased sales of higher-grade HALS and operational efficiencies.
- →HALS revenue target is INR 250-300 crores annually for FY27, making up about 30-35% of overall revenue growth, with export contribution increasing.
- →Performance Chemical 1 plant commercial production and revenue ramp-up expected from Q3 FY27 onwards, with further ramp-up into next year.
- →Performance Chemical 2 plant expected to start commercial production by November (Q3 FY27), with revenue stabilization and growth from Q1 FY28.
- →Strategic tie-ups like the 5-year contract with Kemin and collaboration with Geneus are expected to drive incremental revenues and strengthen margins.
- →Despite raw material price volatility and geopolitical uncertainties, company anticipates steady earnings growth with no expected production stoppages.
- →Overall, profitability and EPS are projected to grow steadily supported by product mix improvements, export growth, and operational ramp-up.
3 more insights locked — sign up free to unlock
Fundraise plans
The transcript does not mention any current or future plans for fundraising through debt or equity. Key points related to capital expenditures and financials are:
- The company invested approximately INR 100 crores as capital infusion in its subsidiary, Clean Fino Chem Limited, during the quarter, with a total investment of around INR 850 crores so far.
- No explicit mention of new debt or equity fundraising was provided.
- Management stated they have not yet worked out detailed plans regarding annual capex run rates or expansions but will inform in due course.
- The company is focusing on operational stability, supply chain management, and ramping up production rather than fundraising at this time.
Hence, no announced or planned fundraising through debt or equity is mentioned in the call.
Order book
- →The transcript does not explicitly mention the current or expected order book or pending orders in quantitative detail.
- →However, Siddharth Sikchi stated that exports to the U.S. have been very steady despite tariff and China competition issues, indicating ongoing strong demand.
- →A strategic 5-year contract with Kemin ensures assured volumes for certain key products, implying a secured portion of the order book with a significant global customer.
- →The HALS business is expected to grow, with a revenue target of INR 250-300 crores for FY27, showing increasing order flow.
- →The Geneus tie-up targets cumulative revenues of around INR 300 crores over four years, indicating ongoing and future order commitments.
- →The Performance Chemicals 2 plant's commercialization is expected around November, with revenue ramp-up anticipated from Q1 FY28.
- →No specific pending order numbers were given, but indications suggest a healthy and growing order pipeline aligned with capacity expansions.
Capex plans
Yes- →INR 100 crores capex invested in subsidiary Clean Fino Chem Limited; all future products and new lines to be developed here.
- →Geneus Chem tie-up involves a capex of about INR 25 crores for a new plant to produce advanced HALS products, expected to start production in Q3 FY27.
- →Additional capacity expansion is planned to meet increased demand from Kemin contract; the process has already started.
- →Performance Chemical 2 plant commercialization expected by Q3 FY27 (November-ish), with stabilization continuing till Q1 FY28.
- →No detailed annual capex run rate provided yet; working on future plans and will update in due course.
How does Clean Science rank vs peers in Chemicals & Petrochemicals?
Pro feature1Clean Science
Rev 3Mar 3
See full Chemicals & Petrochemicals sector rankings
How does Clean Science rank in Chemicals & Petrochemicals?
Compare Clean Science against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.